Visual hypersensitivity in patients treated with anti‐calcitonin gene–related peptide (receptor) monoclonal antibodies
Open Access
- 26 June 2023
- journal article
- research article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (7) , 926-933
Abstract
Objective: To evaluate the effect of treatment with anti‐calcitonin gene–related peptide (CGRP; receptor) antibodies on visual hypersensitivity in patients with migraine. Background: Increased visual sensitivity can be present both during and outside migraine attacks. CGRP has been demonstrated to play a key role in light‐aversive behavior. Methods: In this prospective follow‐up study, patients treated for migraine with erenumab ( n = 105) or fremanezumab ( n = 100) in the Leiden Headache Center were invited to complete a questionnaire on visual sensitivity (the Leiden Visual Sensitivity Scale [L‐VISS]), pertaining to both their ictal and interictal state, before starting treatment (T0) and 3 months after treatment initiation (T1). Using a daily e‐diary, treatment effectiveness was assessed in weeks 9–12 compared to a 4‐week pre‐treatment baseline period. L‐VISS scores were compared between T0 and T1. Subsequently, the association between the reduction in L‐VISS scores and the reduction in monthly migraine days (MMD) was investigated. Results: At 3 months, the visual hypersensitivity decreased, with a decrease in mean ± standard deviation (SD) ictal L‐VISS (from 20.1 ± 7.7 to 19.2 ± 8.1, p = 0.042) and a decrease in mean ± SD interictal L‐VISS (from 11.8 ± 6.6 to 11.1 ± 7.0, p = 0.050). We found a positive association between the reduction in MMD and the decrease in interictal L‐VISS ( β = 0.2, p = 0.010) and the reduction in ictal L‐VISS ( β = 0.3, p = 0.001). Conclusion: A decrease in visual hypersensitivity in patients with migraine after treatment with anti‐CGRP (receptor) antibodies is positively associated with clinical response on migraine.Keywords
This publication has 34 references indexed in Scilit:
- Preventive Migraine TreatmentContinuum, 2015
- Calcitonin Gene-Related Peptide (CGRP): A New Target for MigraineAnnual Review of Pharmacology and Toxicology, 2015
- Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with auraCephalalgia, 2010
- Shared genetic factors in migraine and depressionNeurology, 2010
- Topiramate modulates excitability of the occipital cortex when measured by transcranial magnetic stimulationCephalalgia, 2009
- Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trialThe Lancet, 2008
- Age-dependent prevalence and clinical features of migraineNeurology, 2006
- The validity of the Hospital Anxiety and Depression ScaleJournal of Psychosomatic Research, 2002
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990
- The CES-D ScaleApplied Psychological Measurement, 1977